At a glance
- Originator Takeda
- Developer Abbott Laboratories; Takeda; TAP Pharmaceutical Products
- Class Anti-inflammatories; Disease-modifying antirheumatics; Osteoporosis therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Postmenopausal osteoporosis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 02 Oct 2001 No-Development-Reported for Crohn's disease in USA (Unknown route)
- 02 Oct 2001 No-Development-Reported for Psoriasis in USA (Unknown route)
- 02 Oct 2001 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)